Project Grant F32AI197456
- The National Institute of Allergy and Infectious Diseases awarded The University of Texas Southwestern Medical Center $249,000 on July 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research to develop tools for marginal zone-specific gene expression manipulation in B cells. The project investigates how mature B cell subsets—follicular, marginal zone, and B-1 cells—contribute to protective immune responses in infection and pathogenic responses...
- The National Institute of Allergy and Infectious Diseases awarded $596,318 to The University of Texas Southwestern Medical Center on February 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to define virulence factor functions in Salmonella enterica using minimal pathogen genomes. The research characterizes how a small network of SPI-2 type III secretion system effector proteins coordinate membrane scission of the Salmonella-containing vacuole (SCV) and...
- The National Institute of Allergy and Infectious Diseases awarded the University of California, San Diego $184,693 on August 21, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to advance molecular target identification and optimization of novel small-molecule therapeutics for schistosomiasis. The award funds research to define the mechanism of action and optimize thiophenyl pyrimidine (TPP) analogs as potential alternatives to praziquantel, the single existing...
- The National Institute of Allergy and Infectious Diseases awarded the American Foundation For Biological Research, doing business as the Biomedical Research Institute, $1.8 million on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to operate the Schistosomiasis Resource Center. The Resource Center propagates three medically important Schistosoma species—S. haematobium, S. japonicum, and S. mansoni—and distributes infected hosts (rodents and snails) and...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded The University of Texas Southwestern Medical Center $192,369 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to define CD4+ T-cell populations driving protection and susceptibility in hookworm reinfection. The research will characterize immune mechanisms that prevent parasite clearance in chronic helminth infections, with direct applications to prevention, diagnosis, and...
- The National Institute of Allergy and Infectious Diseases awarded The University of Texas Southwestern Medical Center $249,000 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify conserved antiviral host factors that restrict arbovirus replication across insect and mammalian hosts. The award funds development of an arbovirus rescue assay that screens viral immune evasion proteins (IEPs) encoded by mammalian viruses for their ability to sensitize...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The University of Texas Southwestern Medical Center $451,000 under the Allergy and Infectious Diseases Research program (CFDA 93.855) for a two-year project period (August 1, 2025 – July 31, 2027). This Project Grant supports basic biomedical research investigating how prenatal exposure to maternal helminth (parasitic worm) infections alters immune programming in offspring, with potential...
- The National Institute of Allergy and Infectious Diseases awarded $456,500 to The University of Texas Southwestern Medical Center on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a reproducible sequential infection model that matures laboratory mouse immune responses. The research will define a minimal set of sequential viral and parasitic infections that laboratory mice can be exposed to early in life to recapitulate aspects of wild mice...
- The National Institute of Allergy and Infectious Diseases awarded $149,000 to the University of Puerto Rico Medical Sciences Campus on July 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how Schistosoma mansoni parasites suppress reproduction in Biomphalaria snails, intermediate hosts critical to schistosomiasis transmission. The research addresses parasitic castration—the phenomenon by which trematode infection alters snail reproductive...
- The National Institute of Allergy and Infectious Diseases awarded The University of Texas Southwestern Medical Center $140,910 on May 29, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how testosterone shapes Staphylococcus aureus pathogenesis during bloodstream infections. The research addresses the sex bias in S. aureus bloodstream infection outcomes, where males experience worse disease severity than females. The project investigates molecular...
The National Institute of Allergy and Infectious Diseases awarded The University of Texas Southwestern Medical Center $152,600 on October 7, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to elucidate the molecular and cellular mechanisms by which B-alanyl tryptamine (BATT), a recently discovered schistosome pheromone, triggers female sexual maturation in schistosomes. The recipient will conduct research using transcriptomics, proteomics, and functional assays with Schistosoma mansoni as a model organism. Work encompasses two primary aims: Aim 1 employs complementary genetic and chemical biological approaches to uncover molecular targets of BATT, including systematic screening of schistosome G protein-coupled receptors and development of activity-based probes; Aim 2 uses transcriptomic approaches to define BATT-responsive cell types. The research addresses signaling pathways activated by the pheromone in female worms, which remains largely unknown despite evidence that BATT induces sex organ maturation and egg production. Understanding these mechanisms may inform interventions targeting schistosomiasis, a neglected tropical disease sustained in sub-Saharan Africa and Southeast Asia through egg-laying by mature females. Place of performance is Dallas, Texas. The project period runs from October 7, 2026, through April 7, 2029. This is a Project Grant, the standard NIH research grant vehicle for investigator-initiated biomedical research.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $76.3k | 4/7/26 | ||
| Not listed | $0 | 4/7/26 | ||
| Not listed | $76.3k | 4/7/26 |